Gilead Generates Street Skepticism Ahead of Covid-19 Results
- Remdesivir China data expected this month, U.S. results in May
- Barclays sees 20% chance that Chinese studies will succeed
Bottles of Remdesivir at a hospital in Wuhan, China, in Feb.
Photographer: Yuan Zheng/AP Photo
This article is for subscribers only.
Sign up here for our daily coronavirus newsletter on what you need to know, and subscribe to our Covid-19 podcast for the latest news and analysis.
Results from a study of Gilead Sciences Inc.’s experimental Covid-19 medicine are top-of-mind for Wall Street as cases surpass 1.35 million and deaths approach 76,000.